Antineoplastic effects of auranofin in human pancreatic adenocarcinoma preclinical models
Background: Auranofin, a Food and Drug Administration–approved anti-rheumatic agent with anticancer properties for lung and ovarian cancer, has never been studied for pancreatic cancer. We hypothesize that auranofin may prevent pancreatic ductal adenocarcinoma progression by inhibition of Txnrd1 and...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2019-10-01
|
| Series: | Surgery Open Science |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589845019300119 |